Methyl 5-bromothiophene-2-carboximidate | 1126601-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: Methyl 5-bromothiophene-2-carboximidate
• CAS: 1126601-61-3
• 化学式: C₆H₆BrNOS
• 分子量: 220.09
• InChiKey: GZDBSSIOKOQTPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Methyl 5-bromothiophene-2-carboximidate 在 氯化铵 作用下， 以 乙醇 为溶剂， 生成 5-bromothiophene-2-carboxamidine
  参考文献：
  名称：

  Discovery of selective PDE4B inhibitors

  摘要：

  In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.121
• 作为产物：
  描述：

  甲醇 、 5-溴噻吩-2-甲腈 在 sodium methylate 作用下， 生成 Methyl 5-bromothiophene-2-carboximidate
  参考文献：
  名称：

  Discovery of selective PDE4B inhibitors

  摘要：

  In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.121

文献信息

• Discovery of selective PDE4B inhibitors
  作者：Kenji Naganuma、Akifumi Omura、Naomi Maekawara、Masahiro Saitoh、Naoto Ohkawa、Takashi Kubota、Hiromitsu Nagumo、Toshiyuki Kodama、Masayoshi Takemura、Yuji Ohtsuka、Junji Nakamura、Ryuichi Tsujita、Koh Kawasaki、Hirotsugu Yokoi、Masashi Kawanishi

  DOI：10.1016/j.bmcl.2009.04.121

  日期：2009.6

  In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivatives afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic profile, a selected compound exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast. (C) 2009 Elsevier Ltd. All rights reserved.